The authors show that phosphorylated tau 217 is an accurate blood-based biomarker to detect Alzheimer’s disease and predict disease progression in individuals with Down syndrome, supporting its use as a reliable, non-invasive tool for early diagnosis and care. This evidence concerns the gene MAPT and Alzheimer disease.